Mark W. Arnold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mark W. Arnold has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
Tanios Bekaii-Saab
17 shared publicationsEvan Wuthrick
16 shared publicationsAlan Harzman
15 shared publicationsAmy Webb
15 shared publicationsChristina Wu
15 shared publicationsCynthia Timmers
15 shared publications
Latest Publications
- 2 January 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (2) , 103822
EQIP 2023-2025: Increased Usability and Sustainability
- 2 January 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (2) , 103822
EQIP 2023-2025: Increased Usability and Sustainability
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Table showing next generation sequencing of tumor samples
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Table showing next generation sequencing of tumor samples
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 1 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 1 Flowchart for trial design
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 1 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 1 Flowchart for trial design
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 4 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 4 Baseline p-ERK score in Tumor Tissue Correlated to RAS/RAF Mutation Status
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 4 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 4 Baseline p-ERK score in Tumor Tissue Correlated to RAS/RAF Mutation Status
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Table showing next generation sequencing of tumor samples
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Table showing next generation sequencing of tumor samples
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 3 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 3 Tumor Regression Grade versus Baseline p-ERK score in Tumor Tissue
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 3 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 3 Tumor Regression Grade versus Baseline p-ERK score in Tumor Tissue
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 5 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 5 Degree of Reduction (%) in Tumor pERK Levels From Baseline to After Trametinib Monotherapy and Correlation With pCR
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 5 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 5 Degree of Reduction (%) in Tumor pERK Levels From Baseline to After Trametinib Monotherapy and Correlation With pCR
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 5 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 5 Degree of Reduction (%) in Tumor pERK Levels From Baseline to After Trametinib Monotherapy and Correlation With pCR
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 5 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 5 Degree of Reduction (%) in Tumor pERK Levels From Baseline to After Trametinib Monotherapy and Correlation With pCR
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 4 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 4 Baseline p-ERK score in Tumor Tissue Correlated to RAS/RAF Mutation Status
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 4 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 4 Baseline p-ERK score in Tumor Tissue Correlated to RAS/RAF Mutation Status
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary fig 1 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 1 Flowchart for trial design
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 1 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Supplementary fig 1 Flowchart for trial design